Navigation Links
FDA Announces Possible Safety Concern for HIV Drug Combination
Date:2/23/2010

Review of data indicating life-threatening heart abnormality underway

SILVER SPRING, Md., Feb. 23 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced preliminary data suggesting that Invirase (saquinavir) in combination with Norvir (ritonavir) may have potentially important adverse effects on the heart.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

When used together, the drugs may cause prolongation of the QT and PR intervals on an electrocardiogram. Prolongation of the QT interval may lead to a condition known as torsades de pointes, an abnormal heart rhythm. Prolongation of the PR interval may also lead to an abnormal heart rhythm known as heart block. With torsades de pointes or with heart block, patients may experience lightheadedness, fainting, or abnormal heart beats. In some cases, torsades de pointes may progress to a life-threatening irregular heart beat known as ventricular fibrillation.

Review of the data is ongoing. Preliminary findings suggest that some patients using Invirase and Norvir may be at an increased risk for heart abnormalities leading to irregular heart rhythms. For example, the risk for torsades de pointes may be increased in patients who are also using medications known to cause a heart disturbance called QT interval prolongation. The risk may also be increased in patients who have a history of QT interval prolongation.

Patients using Invirase should talk to their health care professional about any questions or concerns they have about Invirase. Patients and health care professionals should report any side effects from the use of Invirase to the FDA's MedWatch program: http://www.fda.gov/safety/MedWatch/default.htm

Invirase is an antiretroviral medication that was first approved in 1995. Invirase is used in combination with Norvir and other antiretroviral medicines to treat HIV in adults. Invirase does not cure HIV infection, may not prevent you from developing HIV-related illnesses, and may not prevent you from spreading HIV to other people.

This early communication is in keeping with FDA's commitment to inform the public about ongoing safety reviews of drugs. FDA will communicate its findings to the public as soon as the review is complete.

Invirase is marketed by San Francisco-based Genentech, a subsidiary of the Roche Group. Norvir is marketed by Abbott Park, Ill.-based Abbott Laboratories.

For more information:

FDA Drug Safety Communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201221.htm

Drugs@FDA

http://www.fda.gov/Drugs/default.htm

Media Inquiries: Erica Jefferson, 301-796-4988; erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Back to top

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results
2. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
3. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
4. Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes
5. Pioneer(R) Surgical Technology, Inc. Announces New CTO
6. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
7. Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for Its Revolutionary, Patented Symphony(TM) tCGM System
8. Transdel Pharmaceuticals Announces Management Reorganization
9. Solta Medical, Inc. Announces Fourth Quarter 2009 Results Release Date and Conference Call
10. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
11. Sunridge Announces Marketing Roll Out of PNT in the Dominican Republic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016  Nearly 30 million people in ... the epidemic of diabetes. 1 However, nearly 40% ... glucose levels (hyperglycemia) and significant glucose variability. 2 These ... including cardiovascular events. If left untreated, hyperglycemia can lead ... disease or blindness. 3 As part ...
(Date:12/6/2016)... 6, 2016   Sienna Biopharmaceuticals, Inc. ... and aesthetics company, today announced it has ... pharmaceutical company focused on developing first-in-class topical ... psoriasis, atopic dermatitis and pruritus (itch). Under ... make an undisclosed upfront payment in cash ...
(Date:12/6/2016)... 6, 2016  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... focused on the development of novel therapies for ... U.S. Food and Drug Administration (FDA) has granted ... of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a novel, ... selectively regulates the expression of genes believed to ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... ... The Touchpoint Solution’s new neuroscience wearable, Buzzies, generated over $100K in sales online ... $25,000 on Kickstarter to bring to the market what people are calling ... inventor, says she feels like she stumbled upon a miracle that she wants other ...
(Date:12/6/2016)... ... ... Of the variety of ingredients in the food supply, few spark more ... beliefs that hot dogs include “everything but the oink,” today’s wieners are made from ... meat and poultry in a hot dog recipe can add flavor, keep hot dogs ...
(Date:12/6/2016)... ... December 06, 2016 , ... Public middle and high schools ... apply for a 2016/2017 California Casualty Thomas R. Brown Athletics Grant. The application ... receive up to $3,000. , The grant is named after California Casualty ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... charity, is thrilled to formally announce its Not a Moment to Lose fundraising ... Lose will rally supporters dedicated to declaring victory over cancer. The campaign aims ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
Breaking Medicine News(10 mins):